Advertisement

Neuroscience Bulletin

, Volume 34, Issue 5, pp 849–853 | Cite as

Acute Restraint Stress Augments 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurotoxicity via Increased Toxin Uptake into the Brain in C57BL/6 Mice

  • Yasuhide Mitsumoto
  • Atsushi Mori
Report
  • 156 Downloads

Abstract

As an environmental risk factor, psychological stress may trigger the onset or accelerate the progression of Parkinson’s disease (PD). Here, we evaluated the effects of acute restraint stress on striatal dopaminergic terminals and the brain metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which has been widely used for creating a mouse model of PD. Exposure to 2 h of restraint stress immediately after injection of a low dose of MPTP caused a severe loss of striatal dopaminergic terminals as indicated by decreases in the dopamine transporter protein and dopamine levels compared with MPTP administration alone. Both striatal 1-methyl-4-phenylpyridinium ion (MPP+) and MPTP concentrations were significantly increased by the application of restraint stress. Striatal monoamine oxidase-B, which catalyzes the oxidation of MPTP to MPP+, was not changed by the restraint stress. Our results indicate that the enhanced striatal dopaminergic terminal loss in the stressed mice is associated with an increase in the transport of neurotoxin into the brain.

Keywords

MPTP MPP+ Mouse model Restraint stress Dopaminergic neuron Degeneration Dopamine transporter Dopamine 

Notes

Acknowledgements

This work was supported by the Specific Research Foundation of Hokuriku University (250100).

References

  1. 1.
    Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 1999, 22: 123–144.CrossRefPubMedGoogle Scholar
  2. 2.
    Mizuno Y, Yoshino H, Ikebe S, Hattori N, Kobayashi T, Shimoda-Matsubayashi S, et al. Mitochondrial dysfunction in Parkinson’s disease. Ann Neurol 1998, 44: S99–S109.CrossRefPubMedGoogle Scholar
  3. 3.
    Li S, Le W. Milestones of Parkinson’s disease research: 200 years of history and beyond. Neurosci Bull 2017, 33: 598–602.CrossRefPubMedGoogle Scholar
  4. 4.
    Djamshidian A, Lees AJ. Can stress trigger Parkinson’s disease? J Neurol Neurosurg Psychiatry 2014, 85: 878–881.CrossRefPubMedGoogle Scholar
  5. 5.
    Snyder AM, Stricker EM, Zigmond MJ. Stress-induced neurological impairments in an animal model of parkinsonism. Ann Neurol 1985, 18: 544–551.CrossRefPubMedGoogle Scholar
  6. 6.
    Smith AD, Castro SL, Zigmond MJ. Stress-induced Parkinson’s disease: a working hypothesis. Physiol Behav 2002, 77: 527–531.CrossRefPubMedGoogle Scholar
  7. 7.
    Schuurman AG, van den Akker M, Ensinck KT, Metsemakers JF, Knottnerus JA, Leentjens AF, et al. Increased risk of Parkinson’s disease after depression: a retrospective cohort study. Neurology 2002, 58: 1501–1504.CrossRefPubMedGoogle Scholar
  8. 8.
    Janakiraman U, Manivasagam T, Justin Thenmozhi A, Dhanalakshmi C, Essa MM, Song BJ, et al. Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson’s disease. Physiol Behav 2017, 173:132–143.CrossRefPubMedGoogle Scholar
  9. 9.
    Lauretti E, Di Meco A, Merali S, Praticò D. Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson’s disease. Transl Psychiatry 2016, 6: e733.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    de Pablos RM, Herrera AJ, Espinosa-Oliva AM, Sarmiento M, Muñoz MF, Machado A, et al. Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation. J Neuroinflammation 2014, 11: 34.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mori A, Ohashi S, Nakai M, Moriizumi T, Mitsumoto Y. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci Res 2005, 51: 265–274.CrossRefPubMedGoogle Scholar
  12. 12.
    Mitsumoto Y, Mori A, Ohashi S, Nakai M, Moriizumi T. Differential effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the olfactory bulb and the striatum in mice. Neurosci Res 2005, 51: 111–115.CrossRefPubMedGoogle Scholar
  13. 13.
    Desole MS, Esposito G, Fresu L, Migheli R, Enrico P, Miele M et al. Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat. Neurosci Lett 1993, 161: 121–123.CrossRefPubMedGoogle Scholar
  14. 14.
    Suzuki O, Noguchi E, Yagi K. A simple fluorometric assay for type B monoamine oxidase activity in rat tissues. J Biochem 1976, 79: 1297–1299.CrossRefPubMedGoogle Scholar
  15. 15.
    Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003, 39: 889–909.CrossRefPubMedGoogle Scholar
  16. 16.
    McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007, 87: 873–904.CrossRefPubMedGoogle Scholar
  17. 17.
    Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci 2009, 10: 434–445.CrossRefPubMedGoogle Scholar
  18. 18.
    Goncharova ND. Stress responsiveness of the hypothalamic-pituitaryadrenal axis: age-related features of the vasopressinergic regulation. Front Endocrinol 2013, 4: 26.CrossRefGoogle Scholar
  19. 19.
    Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, et al. Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002, 303: 1061–1066.CrossRefPubMedGoogle Scholar
  20. 20.
    Esposito P, Gheorghe D, Kandere K, Pang X, Connolly R, Jacobson S, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001, 888: 117–127.CrossRefPubMedGoogle Scholar
  21. 21.
    Sarmento A, Borges N, Lima D. Influence of electrical stimulation of locus coeruleus on the rat blood-brain barrier permeability to sodium fluorescein. Acta Neurochir (Wien) 1994, 127: 215–219.CrossRefGoogle Scholar
  22. 22.
    Ohata M, Fredericks WR, Sundaram U, Rapoport SI. Effects of immobilization stress on regional cerebral blood flow in the conscious rat. J Cereb Blood Flow Metab 1981, 1: 187–194.CrossRefPubMedGoogle Scholar
  23. 23.
    Roszkowski M, Bohacek J. Stress does not increase blood-brain barrier permeability in mice. J Cereb Blood Flow Metab 2016, 36: 1304–1315.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Urakami K, Masaki N, Shimoda K, Nishikawa S, Takahashi K. Increase of striatal dopamine turnover by stress in MPTP-treated mice. Clin Neuropharmacol 1988, 11: 360–368.CrossRefPubMedGoogle Scholar
  25. 25.
    Li S, Wang Y, Wang F, Hu LF, Liu CF. A new perspective for Parkinson’s disease: circadian rhythm. Neurosci Bull 2017, 33: 62–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Muroyama A, Inaka M, Matsushima H, Sugino H, Marunaka Y, Mitsumoto Y. Enhanced susceptibility to MPTP neurotoxicity in magnesium-deficient C57BL/6 N mice. Neurosci Res 2009, 63: 72–75.CrossRefPubMedGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Laboratory of Alternative Medicine and Experimental Therapeutics, Department of Clinical Pharmacy, Faculty of Pharmaceutical SciencesHokuriku UniversityKanazawaJapan
  2. 2.Department of Perioperative Management SystemNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations